Drotrecogin alfa (activated) is a recombinant form of human activated protein C
that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
Easy to read patient leaflet for drotrecogin alfa. Includes indications, proper use,
special instructions, precautions, and possible side effects.
May 22, 2012 ... There have been conflicting reports on the efficacy of recombinant human
activated protein C, or drotrecogin alfa (activated) (DrotAA), for the ...
Learn about drug side effects and interactions for the drug Xigris (Drotrecogin
Sep 22, 2004 ... On 25 October 2011, Eli Lilly and Company announced the withdrawal of its
Xigris (drotrecogin alfa [activated]) product in all markets following ...
Drug information on Xigris (drotrecogin alfa), includes drug pictures, side effects,
drug interactions, directions for use, symptoms of overdose, and what to avoid.
Oct 25, 2011 ... FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [
drotrecogin alfa (activated)] due to failure to show a survival benefit.
Drotrecogin alfa is activated human protein C that is synthesized by recombinant
DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular ...
Drotrecogin alfa [recombinant Human Activated Protein C (Xigris™)], was
recently approved by the FDA for the reduction of mortality in adult patients with
Demographic characteristics and average acute physiology and chronic health
evaluation (APACHE II) scores were much the same in the randomised clinical ...